At a glance
- Originator Biomeasure Inc; Institut de la Recherche sur le Cancer; Institut Henri Beaufour-Ipsen; Universite Libre de Bruxelles
- Class Camptothecins
- Mechanism of Action DNA topoisomerase I inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Jul 1999 Preclinical development for Cancer in Europe (Unknown route)